Table 3.
Descriptive Statistics of Cohort Stratified by Whether MDT Recommended Management Changed as a Result of COVID-19 (n = 975)
| Characteristic | No, n = 871a | Yes, n = 104a | P-valueb |
|---|---|---|---|
| Age | .889 | ||
| 16–19 | 4 (0.5%) | 1 (1.0%) | |
| 20–29 | 31 (3.6%) | 4 (3.8%) | |
| 30–39 | 58 (6.7%) | 6 (5.8%) | |
| 40–49 | 94 (11%) | 10 (9.6%) | |
| 50–59 | 210 (24%) | 25 (24%) | |
| 60–69 | 243 (28%) | 24 (23%) | |
| 70–79 | 190 (22%) | 27 (26%) | |
| 80–89 | 41 (4.7%) | 7 (6.7%) | |
| Sex | >.9 | ||
| Female | 445 (51%) | 52 (50%) | |
| Male | 426 (49%) | 52 (50%) | |
| ECOG | .4 | ||
| 0 | 388 (45%) | 43 (42%) | |
| 1 | 317 (37%) | 33 (32%) | |
| 2 | 129 (15%) | 22 (22%) | |
| 3 | 24 (2.8%) | 4 (3.9%) | |
| 4 | 4 (0.5%) | 0 (0%) | |
| Presentation | .042 | ||
| New diagnosis | 677 (78%) | 71 (68%) | |
| Recurrence | 194 (22%) | 33 (32%) | |
| New diagnosis—radiological diagnosis | .085 | ||
| High-grade glioma | 193 (29%) | 23 (32%) | |
| Low-grade glioma | 48 (7.1%) | 10 (14%) | |
| Meningioma | 124 (18%) | 16 (23%) | |
| Metastasis | 238 (35%) | 14 (20%) | |
| Other | 34 (5.0%) | 2 (2.8%) | |
| Primary CNS lymphoma | 30 (4.4%) | 5 (7.0%) | |
| Vestibular schwannoma | 9 (1.3%) | 1 (1.4%) | |
| Recurrence—original histopathology | .002 | ||
| Glioma | 86 (44%) | 24 (73%) | |
| Meningioma | 22 (11%) | 3 (9.1%) | |
| Metastasis | 62 (32%) | 1 (3.0%) | |
| Other | 17 (8.8%) | 3 (9.1%) | |
| Primary CNS lymphoma | 2 (1.0%) | 1 (3.0%) | |
| Vestibular schwannoma | 5 (2.6%) | 1 (3.0%) | |
| SARS–CoV-2 suspected at time of MRI diagnosis | 16 (1.8%) | 3 (2.9%) | .4 |
aStatistics presented: n (%).
b Statistical tests performed: chi-square test of independence; Fisher's exact test.